Skip to main content
Caplight Logo









Disperazol Pharma ApS

Disperazol Pharma ApS

Private
HumlebækHealthcare & Life Scienceshttps://www.disperazolpharma.com/

Last Round

Grant

Jun 5, 2023

Total Funding Raised

$10,800

Company Overview

Disperazol Pharma ApS is a biotechnology company that develops non-traditional antimicrobial compounds designed to dismantle biofilms of Gram-negative pathogens to enhance the efficacy of existing antibiotics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

AMRantimicrobial resistancebiofilm dispersalantibiotic resistancebacterial biofilmsGram-negative pathogenssuperbug treatmentc-di-GMP signalingdrug discoverybiotech R&Dantibiotic adjuvantphosphodiesterase activationbiotech spinout

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Disperazol Pharma ApS Comparables

Compare Disperazol Pharma ApS with similar companies based on industry and business-model similarity.

Disperazol Pharma ApS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BioTryp Therapeutics
85%
Resistia
82%
HHV Biotech
80%

Disperazol Pharma ApS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 5, 2023

Key People

Founding team and executive leadership

Michael Graz

Co-Founder and CEO

Founding Team

Disperazol Pharma ApS Investors

Notable investors and investment history

Disperazol Pharma ApS investors
InvestorRounds
INCATEGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Monthly visitors grew 416% MoM, from 251 to 1.3K.

  • Jun 5, 2023

    $11K grant received from INCATE.

Disperazol Pharma ApS Filings

Explore SEC and related filing metadata, where available.

Disperazol Pharma ApS filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Disperazol Pharma ApS's valuation, stock price, and market status.

Is Disperazol Pharma ApS a public or private company?

Disperazol Pharma ApS is a private company.

What is the current stock price of Disperazol Pharma ApS?

Disperazol Pharma ApS is a private company with no public stock price. Caplight tracks Disperazol Pharma ApS's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Disperazol Pharma ApS worth (valuation)?

Valuation information for Disperazol Pharma ApS is not publicly available.

Can I buy Disperazol Pharma ApS stock?

Disperazol Pharma ApS shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Disperazol Pharma ApS's last funding round?

Disperazol Pharma ApS's most recent funding round was Grant on June 5, 2023.

Who are the main investors in Disperazol Pharma ApS?

Key investors in Disperazol Pharma ApS include INCATE.

Will Disperazol Pharma ApS IPO soon?

No public IPO plans have been announced for Disperazol Pharma ApS.

How can I track Disperazol Pharma ApS secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Disperazol Pharma ApS's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHumlebæk
Employee Range1
Year Founded2023
Last FundingJun 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?